| Cutting-Edge Therapeutics Limited |
| Registered number: |
10146338 |
| Balance Sheet |
| as at 30 April 2020 |
|
| Notes |
|
|
2020 |
|
|
2019 |
| £ |
£ |
| Fixed assets |
| Tangible assets |
3 |
|
|
1,466 |
|
|
1,833 |
|
| Current assets |
| Cash at bank and in hand |
|
|
12,440 |
|
|
21,386 |
|
| Creditors: amounts falling due within one year |
4 |
|
(9,085) |
|
|
(23,478) |
|
| Net current assets/(liabilities) |
|
|
|
3,355 |
|
|
(2,092) |
|
| Net assets/(liabilities) |
|
|
|
4,821 |
|
|
(259) |
|
|
|
|
|
|
|
|
| Capital and reserves |
| Called up share capital |
|
|
|
100 |
|
|
100 |
| Profit and loss account |
|
|
|
4,721 |
|
|
(359) |
|
| Shareholders' funds |
|
|
|
4,821 |
|
|
(259) |
|
|
|
|
|
|
|
|
| The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
| The members have not required the company to obtain an audit in accordance with section 476 of the Act. |
| The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
| The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies. |
|
|
|
|
| Zahid Sattar |
| Director |
| Approved by the board on 9 April 2021 |
|
| Cutting-Edge Therapeutics Limited |
| Notes to the Accounts |
| for the year ended 30 April 2020 |
|
|
| 1 |
Accounting policies |
|
|
Basis of preparation |
|
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard). |
|
|
Turnover |
|
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. |
|
|
Tangible fixed assets |
|
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows: |
|
|
Fixtures, fittings, tools and equipment |
20% reducing balance |
|
|
Creditors |
|
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs. |
|
|
Functional and presentation currency |
|
The financial statements of the company are measured and presented in the currency of the primary economic environment in which the company operates, the functional currency. The financial statements are presented in Pound sterling (£), which is the company’s functional currency. |
|
|
Taxation |
|
A current tax liability is recognised for the tax payable on the taxable profit of the current period. |
|
|
| 2 |
Employees |
2020 |
|
2019 |
| Number |
Number |
|
|
Average number of persons employed by the company |
2 |
|
2 |
|
|
|
|
|
|
|
|
|
|
| 3 |
Tangible fixed assets |
|
|
|
|
|
|
|
|
Fixtures, fittings, tools and equipment |
| £ |
|
Cost |
|
At 1 May 2019 |
2,803 |
|
At 30 April 2020 |
2,803 |
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
At 1 May 2019 |
970 |
|
Charge for the year |
367 |
|
At 30 April 2020 |
1,337 |
|
|
|
|
|
|
|
|
|
|
Net book value |
|
At 30 April 2020 |
1,466 |
|
At 30 April 2019 |
1,833 |
|
|
| 4 |
Creditors: amounts falling due within one year |
2020 |
|
2019 |
| £ |
£ |
|
|
Trade creditors |
122 |
|
9,240 |
|
Corporation tax |
7,564 |
|
10,708 |
|
Other taxes and social security costs |
1,398 |
|
3,521 |
|
Other creditors |
1 |
|
9 |
|
|
|
|
|
|
9,085 |
|
23,478 |
|
|
|
|
|
|
|
|
|
|
| 5 |
Related party transactions |
|
|
The director and his wife are the only related parties. They have taken salaries and dividends which are disclosed in the accounts. |
|
|
| 6 |
Controlling party |
|
|
The director does not consider there to be an ultimate controlling party. |
|
|
| 7 |
Other information |
|
|
Cutting-Edge Therapeutics Limited is a private company limited by shares and incorporated in England. Its registered office is: |
|
|
Suite 4, Cranbrook House |
|
61 Cranbrook Road |
|
Ilford |
|
Essex |
|
IG1 4PG |
